Company files for diabetes drug application

A diabetes drug company has filed a new drug application with the Food and Drug Administration (FDA) in America. The new drug, submitted by Lexicon Pharmaceuticals Inc. is designed to treat type 2 diabetes cases.
Following a review by the FDA, the oral drug is going to be put through phase 1 clinical trials to further assess its efficiency. Lexicon are a biopharmaceutical company committed to developing new drug treatments.
The executive vice president and chief scientific office of Lexico, Brian Zambrowicz, reportedly commented: “The mechanism of action of LX4211 specifically blocks reabsorption of glucose by the kidney, which may help to improve glucose control in patients with type 2 diabetes .”